Status: retired, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Mar 2023. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 1765262011 | Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality) | en | Fully specified name | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 1773087011 | Therapy-related acute myeloid leukaemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 1774373010 | Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 1785804014 | Therapy-related AML and myelodysplastic syndrome, topoisomerase type II inhibitor-related type | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 3492361000005110 | behandlingsrelateret akut myeloid leukæmi og myeloblastært syndrom af topoisomerase type II-inhibitor-relateret type | da | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | Danish module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| behandlingsrelateret akut myeloid leukæmi og myeloblastært syndrom af topoisomerase type II-inhibitor-relateret type | Is a | behandlings-relateret akut myeloid leukæmi og myelodysplastisk syndrom | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| A subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposide, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving the mixed lineage leukaemia gene at 11q23. This subgroup of t-MN is typically associated with overt leukaemia, without preceding myelodysplastic syndrome, developing 2-3 years after exposure, presenting with non-specific symptoms related to ineffective haematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement. | Associated morphology | False | behandlingsrelateret akut myeloid leukæmi og myeloblastært syndrom af topoisomerase type II-inhibitor-relateret type | Inferred relationship | Some | 1 |
Reference Sets
Concept inactivation indicator reference set
Description inactivation indicator reference set
SAME AS association reference set (foundation metadata concept)
FHIR